- Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
-
Kim H, Yun T, Lee YJ, Han JY, Kim HT, Lee GK
- KMID: 1777655
- J Korean Med Sci.
- 2013 Nov;28(11):1595-1602.
- doi: 10.3346/jkms.2013.28.11.1595
Most patients with tyrosine kinase inhibitor (TKI)-sensitive non-small cell lung cancer (NSCLC) eventually develop acquired resistance to TKIs. Factors that affect TKI-sensitive patient survival after progression during TKI treatment remain... -
- CITED
-
- Close
- SHARE
-
- Close
